| 配分額 *注記 |
4,680千円 (直接経費: 3,600千円、間接経費: 1,080千円)
2022年度: 2,730千円 (直接経費: 2,100千円、間接経費: 630千円)
2021年度: 1,950千円 (直接経費: 1,500千円、間接経費: 450千円)
|
|---|
| 研究実績の概要 |
Using the Alzheimer’s disease (AD) model (APPNL-G-F mice) developed by the RIKEN, which demonstrates pathological phenotypes of human patients with AD, we aimed to investigate whether a long-term combined intervention of light-intensity exercise (LE) and astaxanthin (ASX) intake facilitate the hippocampal-dependent neural plasticity and subsequent cognitive enhancement in AD, thereby elucidating the role of brain-genic leptin (LEP) as a potential molecule target. We investigated pathological phenotypes and LEP expression shown in age-matched wild-type mice as a control, APPNL-G-F and APPNL-G-F treated with LE, and APPNL-G-F mice combined-treated with LE and ASX. It revealed that the pathological phenotypes featured by the impaired spatial memory in Morris water maze test and the accumulation of amyloid β-peptide as well as the overexpression of LEP in the hippocampus, might be reversed by combined treatment of LE and ASX. Furthermore, we found the synergistic improvement in the hippocampal neurogenesis and BDNF expression by combined treatment of LE and ASX of APPNL-G-F mice. However, we are still confronting the growing debates about whether the source of LEP detected in the brain is actually the brain. To reveal the origin of LEP, we established an in situ hybridization technique, and as of now, we have made great progress on this and tentatively succeeded in labeling LEP mRNA in hippocampal CA2/3 region. There is a lot to unravel, but these findings will give a new insight into hippocampal neuroplasticity mediated by LEP in patients with AD.
|
